BrightAccountsProduction v1.0.0 v1.0.0 2024-01-01 The company was not dormant during the period The company was trading for the entire period The principal activity of the company continued to be that of a specialist supplier of clinical trails comparators. 29 September 2025 5 10 08388917 2024-12-31 08388917 2023-12-31 08388917 2022-12-31 08388917 2024-01-01 2024-12-31 08388917 2023-01-01 2023-12-31 08388917 uk-bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 08388917 uk-curr:PoundSterling 2024-01-01 2024-12-31 08388917 uk-bus:AbridgedAccounts 2024-01-01 2024-12-31 08388917 uk-core:ShareCapital 2024-12-31 08388917 uk-core:ShareCapital 2023-12-31 08388917 uk-core:RetainedEarningsAccumulatedLosses 2024-12-31 08388917 uk-core:RetainedEarningsAccumulatedLosses 2023-12-31 08388917 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2024-12-31 08388917 uk-core:TotalEquityAttributableToOwnersParentBeforeNon-controllingInterests 2023-12-31 08388917 uk-bus:FRS102 2024-01-01 2024-12-31 08388917 uk-core:Buildings 2024-01-01 2024-12-31 08388917 uk-core:FurnitureFittingsToolsEquipment 2024-01-01 2024-12-31 08388917 uk-bus:Audited 2024-01-01 2024-12-31 08388917 uk-core:CostValuation 2023-12-31 08388917 uk-core:AdditionsToInvestments 2024-12-31 08388917 uk-core:CostValuation 2024-12-31 08388917 uk-core:Subsidiary1 2024-01-01 2024-12-31 08388917 uk-core:Subsidiary2 2024-01-01 2024-12-31 08388917 2024-01-01 2024-12-31 08388917 uk-bus:Director2 2024-01-01 2024-12-31 08388917 uk-bus:Director3 2024-01-01 2024-12-31 xbrli:pure iso4217:GBP xbrli:shares
 
 
 
Orifarm Healthcare UK Ltd
 
Abridged Financial Statements
 
for the financial year ended 31 December 2024



ORIFARM HEALTHCARE UK LTD
Company Registration Number: 08388917
ABRIDGED BALANCE SHEET
as at 31 December 2024

2024 2023
Notes £ £
 
Fixed Assets
Tangible assets 6 63,967 98,848
Investments 7 2,027,215 38,035
───────── ─────────
Fixed Assets 2,091,182 136,883
───────── ─────────
 
Current Assets
Debtors 4,394,376 4,298,366
Cash and cash equivalents 4,637 122,282
───────── ─────────
4,399,013 4,420,648
───────── ─────────
Creditors: amounts falling due within one year (4,348,807) (2,658,404)
───────── ─────────
Net Current Assets 50,206 1,762,244
───────── ─────────
Total Assets less Current Liabilities 2,141,388 1,899,127
═════════ ═════════
 
Capital and Reserves
Called up share capital 2,000,200 200
Retained earnings 141,188 1,898,927
───────── ─────────
Shareholders' Funds 2,141,388 1,899,127
═════════ ═════════
 
The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A (Small Entities).
           
All of the members have consented to the preparation of abridged accounts in accordance with section 444(2A) of the Companies Act 2006.
           
The company has taken advantage of the exemption under section 444 not to file the Abridged Profit and Loss Account and Directors' Report.
           
Approved by the Board and authorised for issue on 29 September 2025 and signed on its behalf by
           
           
           
________________________________     ________________________________
Hans Carl Bogh-Sorensen     Mads Fink Eriken
Director     Director
           



ORIFARM HEALTHCARE UK LTD
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2024

   
1. General Information
 
Orifarm Healthcare UK Ltd is a company limited by shares incorporated and registered in the United Kingdom. The registered number of the company is 08388917. The registered office of the company is Ground floor, Suite A2, Breakspear Way, Breakspear Park, Hemel Hempstead, Hertfordshire, HP2 4TZ. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Pound (£) which is also the functional currency of the company.
         
2. Summary of Significant Accounting Policies
 
The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.
 
Statement of compliance
The financial statements of the company for the financial year ended 31 December 2024 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2006.
 
Basis of preparation
The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets.
 
Consolidated accounts
The company is entitled to the exemption in Section 399 of the Companies Act 2006 from the obligation to prepare group accounts.
 
Turnover
Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.
 
Finance income
Interest income is recognised using the effective interest method. The company participates in a group cash pooling arrangement operated by the group’s bankers. Under this arrangement, interest is allocated by the parent company to the participants in proportion to their pooled balances. The company’s share of such interest is recognised within finance income as it accrues.
 
Tangible assets and depreciation
Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:
 
  Short leasehold property - 2% Straight line
  Fixtures, fittings and equipment - 15% Straight line
 
The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.
 
Investments
Investments held as fixed assets are stated at cost less provision for any permanent diminution in value. Income from other investments together with any related tax credit is recognised in the Profit and Loss Account in the financial year in which it is receivable.
 
Trade and other debtors
Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.
 
Borrowing costs
Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.
 
Trade and other creditors
Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.
 
Employee benefits
The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.
 
Taxation and deferred taxation
Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements. Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.
 
Foreign currencies
Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.
 
Ordinary share capital
The ordinary share capital of the company is presented as equity.
   
3. Significant accounting judgements and key sources of estimation uncertainty
 
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
   
4. INFORMATION RELATING TO THE AUDITOR'S REPORT
 
The Audit Report was unqualified. There were no matters to which the auditor was required to refer by way of emphasis.
 
The financial statements were audited by WestMore Accounting Limited.
The Auditor's Report was signed by Simon Weston (Senior Statutory Auditor) for and on behalf of WestMore Accounting Limited on 29th September 2025.
 
       
5. Employees
 
The average monthly number of employees, including directors, during the financial year was 5, (2023 - 10).
 
  2024 2023
  Number Number
 
Staff 5 10
  ═════════ ═════════
         
6. Tangible assets
  Short Fixtures, Total
  leasehold fittings and  
  property equipment  
  £ £ £
Cost
At 1 January 2024 34,426 123,663 158,089
Additions - 2,054 2,054
  ───────── ───────── ─────────
At 31 December 2024 34,426 125,717 160,143
  ───────── ───────── ─────────
Depreciation
At 1 January 2024 10,084 49,157 59,241
Charge for the financial year 8,607 28,328 36,935
  ───────── ───────── ─────────
At 31 December 2024 18,691 77,485 96,176
  ───────── ───────── ─────────
Net book value
At 31 December 2024 15,735 48,232 63,967
  ═════════ ═════════ ═════════
At 31 December 2023 24,342 74,506 98,848
  ═════════ ═════════ ═════════
       
7. Investments
  Group and Total
  participating  
  interests/  
  joint ventures  
Investments £ £
Cost
At 1 January 2024 38,035 38,035
Additions 1,989,180 1,989,180
  ───────── ─────────
At 31 December 2024 2,027,215 2,027,215
  ───────── ─────────
Net book value
At 31 December 2024 2,027,215 2,027,215
  ═════════ ═════════
At 31 December 2023 38,035 38,035
  ═════════ ═════════
             
7.1. Holdings in related undertakings

The company holds 20% or more of the share capital of the following companies:
 
  Country Nature   Details Proportion
  of of   of held by
Name incorporation and address of Registered Office business   investment company
 
Subsidiary undertaking
Orifarm US, Inc America Pharmaceutical suppliers   Ordinary shares 100
 
PCS GmbH Germany Dormant   Ordinary shares 100
 
 
In the opinion of the directors, the value to the company of the unlisted investments is not less than the book amount shown above.
       
8. Capital commitments
 
The company had no other material capital commitments at the financial year-ended 31 December 2024 other than that outlined at note 9.
   
9. Post-Balance Sheet Events
 
There have been no significant events affecting the company since the financial year-end.